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Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of death
worldwide. Alveolar wall destruction is a significant contributor to COPD. Inflamma-
tory macrophages are a major source of the Extracellular Matrix (ECM) proteolysis.
ECM breakdown causes air to get trapped in the alveoli, obstructing airflow. One step
in curing COPD may be to convert inflammatory to pro-regenerative macrophages.
Decellularized ECM scaffolds have shown the ability to induce a pro-regenerative
phenotype.
Yet these scaffolds are incapable for reaching the alveolar region of the lungs.
To reach the alveolar region particles need a diameter of 1-5 μm or smaller than 300
nm. We used protein from decellularized lung tissue to create nanoparticles. By
first digesting the protein in acid, we electrosprayed the solution into nanoparticles.
The average size of the nanoparticles is 225 (± 67) nm, within the requirements to
reach alveoli. However, another barrier exists for treating this disease. That barrier
is mucus; mucus hypersecretion is another sign of COPD. The formed particles can
penetrate the mucus layer in COPD.
After characterizing the particles, we began in vitro investigations. First, we mea-
sured cytotoxicity of the nanoparticles. In alveolar epithelial cells, adding nanoparti-
cles to the media increased cellular proliferation. We then added the nanoparticles to
isolated murine macrophages. The nanoparticles induced a pro-regenerative pheno-
typic shift in murine macrophages. These experiments reveal that these nanoparticles
may become an effective treatment for degenerative lungs diseases, such as COPD,
after further investigation.
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1.1 Chronic Obstructive Pulmonary Disease
Lung disease continues to increase at dramatic rates. Chronic Obstructive Pul-
monary Disease (COPD) alone is the third leading cause of death in the United States
[1]. COPD is incurable and worsens over time, even with treatment. Lung transplants
provide the only option for curing lung diseases, but high rejection rates [2, 3, 4, 5]
and lack of suitable donors [5, 6, 7] mar successful lung transplants.
Pathological changes in COPD include abnormal inflammatory immune response
[8], unchecked apoptosis [9, 10], hypersecretion of mucus [11, 12], increased bacterial
infections [13], characteristic destruction of the extracellular matrix (ECM) in the
alveolar basement membrane [9, 14], and increased proliferation and phenotypic shift
to inflammatory macrophages [15, 16]. Each change provides a unique set of obstacles
for treating the disease, and few treatments can reach and treat the disease.
1.1.1 COPD pathology: apoptosis
In COPD, alveolar cells undergo significantly more apoptosis compared to non-
smokers and “healthy” smokers [18]. Yet even after smoking cessation, apoptosis of
epithelial cells and T lymphocytes persists [19]. Chronic exposure to pollution and
cigarette smoke causes cells to release cytokines, which cause epithelial and endothelial
pneumocyte apoptosis [16]. Under normal circumstances macrophages would clear
apoptotic cells, but COPD decreases the phagocytic abilities of macrophages [13,
9, 20]. When apoptotic cells are not removed, necrosis can occur, leading to more
inflammation [21]. Some of the factors released through necrosis increase autophagy of
epithelial cells leading to increased mucus production [22], or epithelial cell metaplasia
into mucus secreting goblet cells [23].
2
Figure 1. Cigarette smoke and pollution cause lung diseases, such as Chronic Obstructive
Pulmonary Disease. Pathological changes in COPD include hypersecretion of mucus, airway
lumen narrowing, and alveolar wall destruction. (Reproduced with permission from [17])
3
Figure 2. Cigarette smoke alters lung microenvironment through epithelial cells and
macrophages. Cigarette smoke causes inflammatory cytokine and protease release from
epithelial cells and alveolar macrophages. The released small molecules contribute to the
alveolar wall destruction, cellular reprogramming, apoptosis, and mucus hypersecretion in
the pathology of COPD.
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1.1.2 COPD pathology: hypersecretion of mucus
Chronic stimulation of the innate immune system results in both increased pro-
duction (hypersecretion) and decreased clearance of mucus [10, 12]. When combined,
increased mucus and decreased transport can form a mucus plug, blocking smaller
airways [10, 12]. The added mucus acts as both a barrier to therapeutic delivery and
encourages bacterial colonization [12].
Mucus is an effective barrier to prevent foreign materials from contacting the
epidermal layer. It is an adhesive, tenacious, viscoelastic gel required for maintaining
airway hydration and entrapping foreign objects. Single mucin proteins form mucus
polymers that tangle together to form semipermeable networks. In diseases such
COPD, a secondary network of DNA or actin can form [24], increasing the viscosity
of the mucus. Increases in the viscosity cause decreased mucus clearance, allowing
trapped bacteria to colonize.
1.1.3 COPD pathology: bacterial infections
A significant proportion of patients with COPD have lower airway bacterial col-
onization [25, 26]. Increased bacterial colonization establishes a vicious cycle of ep-
ithelial cell damage, impaired mucus clearance, mucus hypersecretion, increased sub-
mucosal vascular leakage and inflammatory cell infiltration, promoting further dys-
function of host defenses and bacterial adherence and growth [26]. Most exacerbation
occurs in patients with Haemophilus influenzae colonization, yet other bacterium,
such as Streptococcus pneumoniae, also exist in patient sputum cultures [13, 26, 27].
Again, under normal circumstances macrophages would remove the bacterial colonies,
but COPD decreases the phagocytic abilities of macrophages [9, 13, 20].
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1.1.4 COPD pathology: macrophages
The diffusion distance for gas exchange would be compromised if mucus was
produced in the alveoli. Thus instead of mucus, roaming alveolar macrophages
protect the alveoli. There is increasing evidence that macrophages orchestrate tis-
sue inflammation through the release of chemokines and proteases in COPD [28].
Macrophages exist as a heterogeneous spectrum of cell phenotypes with classically
activated macrophages (M1) or alternatively activated macrophages (M2) represent-
ing the extreme polarizations possible. But macrophage polarization is dynamic,
with macrophages working together to keep homeostasis. M1 macrophages produce
increased nitric oxide, attack foreign objects, and cause inflammation resulting in
tissue degradation. Besides inflammatory cytokines, acute infections of Streptococ-
cus spp. induce M1-like macrophage phenotypes [29, 30]. However, M2 macrophages
increase ornithine production, increase proliferation, and rebuild tissue. Both polar-
izations exist in small quantities to support homeostatic conditions. In the COPD
lung, an additional 40% of the resident, normally na¨ıve, alveolar macrophages shift to
M1-like macrophages [31]. M1-like macrophages initiate the proteolytic degradation
of the basement membrane seen in pathologies like COPD and increase by 5-10 fold
in the COPD lung [15, 16].
1.1.5 COPD pathology: proteolytic degradation of the extracellular ma-
trix
The basement membrane, comprised of proteins and glycosaminoglycans, holds
the epithelial layer of cells in place. Chronic inflammation of the small airways leads
to elastolysis of the basement membrane, detaching the alveoli from parenchyma.
During respiration this detachment enables bronchiolar lumen collapse before alveolar
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collapse, leaving some sacs inflated. Inflated or partially inflated alveoli obstruct
respiration [32]. Regional cellular changes are at the root of these macroscopic effects.
1.2 Treatment considerations
Significant obstacles prevent the majority of therapeutics from being successful
in treating lung diseases. The lungs are difficult to target via intravenous (IV) or
ingestion routes due to first pass metabolism, proteolysis, and systemic translocation.
Aerosolized therapeutics are drugs in a pressurized enclosure released as a fine spray.
Patients are receiving only about 30% total lung deposition from the best inhaled
formulations [33]. Barriers to aerosol deposition include a labyrinth of airways and
mucus-lined tracts. Pathologies like COPD enhance these obstacles through airway
inflammation causing the lumen diameter to narrow, and hypersecretion of mucus,
narrowing the airways further.
1.2.1 Treatment considerations: particle size
Before a therapeutic can attempt to treat COPD, it must first make it to the
bronchoalveolar regions. Mean mass aerodynamic diameter (MMAD) is the current
standard for determining regional deposition fractions. The particle mass is averaged
about the aerodynamic diameter to calculate the MMAD. Tailoring drug sizes is the
most effective way to passively target different regions of the lungs due to aerody-
namics. To get past the trachea particulate size must be <10 μm, past the bronchi
<5 μm. Many reports describe exhalation of particles smaller than 1 μm before depo-
sition [34, 35, 36]. However, a bimodal distribution for alveolar deposition has been
experimentally proven, modeled, and reviewed (Figure 3) [37, 38, 39, 40].
Optimal drug sizes for alveolar deposition range occur at the peaks 2.3 μm and
50 nm, but nanoparticles smaller than 500 nm normally reach the alveolar region by
7
Figure 3. Experimental and mathematical modeling of particle deposition. Images re-
produced from [39, 40, 41, 38].
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diffusion [42]. Other modeling simulations show alveolar deposition peak between
1.5 μm and 3 μm based on breathing techniques, but include a significant increase
in particle deposition as diameter decreases below 100nm [41]. But to treat the
entire lung, a heterogeneous size distribution would deposit particles throughout the
airways maintaining the size below 5 μwith a majority in the nanometer range. In
COPD, patients nanoparticles achieved 62% lung deposition, with over 33% delivered
to the peripheral region [43]. Nanoparticles improve deposition in asthmatics and
COPD patients [33, 44]. Besides size, particle charge can change the deposition of
nanoparticles through agglomeration, uptake and cytotoxicity.
1.2.2 Treatment considerations: surface charge
Particle surface charge is a secondary determiner for deposition location [38].
Zeta potential (ζ-potential) is a measure of the particle surface charge. Results from
ζ-potential investigations are indicators of conglomeration, cellular uptake, and cyto-
toxicity (Figure 4). Increasing the magnitude of ζ-potential away from zero reduces
particle stability without agglomeration. Either highly charged positive particles or
highly charged negative particles will resist nanoparticle clustering. Cellular uptake
of particles is increases with positive surface charge, for faster delivery of therapeu-
tics. Cell membranes are anionic, therefore a positive surface charge of nanoparticles
increases cellular attraction, increasing cellular uptake. A more negative charge in
2.5 μm microparticles -81 mV compared to -26 mV causes around three times slower
uptake by alveolar macrophages [45]. However, increases in nanoparticle absolute
magnitude of ζ-potential increases macrophage cytotoxicity [46, 47, 48]. Therefore, a
mild negative charge (around -10 mV) would allow for increased cellular uptake and
decreased cytotoxicity.
9
Figure 4. General considerations for creating nanoparticles. From [49]. However,
when aerosolizing to deliver to the lungs additional barriers such as mucus and alveolar
macrophages must be taken into account.
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1.2.3 Treatment considerations: mucus penetration
Once a particle is tailored for the correct deposition size, the next obstacle inhaled
particles face is respiratory fluid, including mucus, edematous fluid, and fluid from
damaged epithelial barriers. Regardless of deposition site inhaled particulate will
come in contact with some lung fluid [50]. Mucus has long been a barrier for inhaled
therapeutic effectiveness. Many nanoparticles designed for respiratory delivery are
positively charged and hydrophobic, making them ideal substances for mucus to trap
and sweep up to the esophagus via the mucocilliary escalator. Factors influencing
mucus transport include the following characteristics: mucociliary transport rate of 5
mm·min−1 [51]; mucus thickness of 2-10 μm [52]; and distance from alveoli to trachea
150 mm [37]. Under normal circumstances it would take mucus 30 minutes to go
from terminal bronchioles to the trachea. However, inhaled nanomaterials which are
insoluble in mucus and lining fluid, cannot be rapidly absorbed, and may undergo
physical translocation [53].
1.2.4 Treatment considerations: macrophages
Upon deposition of particulate, roaming macrophages become another barrier
for all inhaled particulate. Macrophages identify and dispose of foreign particulate,
or they begin an inflammatory response to form granulation around particulate that
cannot be endocytosed or enzyme digested. Macrophage phagocytosis is maximal for
particulate around 2 μm [46, 54], while reduced endocytosis occurs with particulate
smaller than 260 nm [55]. Identification of particles as foreign is not only size based
but also surface charge, and composition based.
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1.2.5 Treatment considerations: particle composition
Successful drug release depends on carrier type, and release mechanics, and safety
depends on degradation and removal of the carrier. Carrier release mechanics are as
important as the MMAD to ensure proper therapeutic release. Drugs can be released
from carriers via carrier integration, diffusion, separation, erosion or degradation of
the carrier. Carrier integration occurs when a vehicle integrates with a cellular lipid
bilayer. This integration results in direct release of drug into the cell and is the typical
release mechanism of lipid nanoparticles. Diffusion occurs via activation of pores on
the carrier surface, leading to release of the drug. Separation can occur when a drug
has a weak attachment to a carrier, and a reagent replaces the drug which is then
released from the carrier. Erosion can occur through creating a carrier that degrades
over time, or breaks down in the presence of common enzymes or ions.
Carriers can be built to be specifically targeted by macrophages or lysosomes, to
degrade the carrier. Additional drug release characteristics can be tailored to release
using pH, temperature, composition, ultrasound, attachment to relatively drugs to
delay absorption [56], or through the creation of an insoluble complex, such as with
insulin and zinc chloride [57].
1.2.5.1 Lipids
The advantages of biocompatibility, biodegradation, sustained drug release have
caused many labs to investigate lipid nanoparticles for pulmonary drug delivery ap-
plications [58]. There are three types of lipid nanoparticles: solid lipid nanoparticles,
micelles, and liposomes. Because there are three different types, both hydrophobic
and hydrophilic therapeutics can be incorporated. Insulin entrapped in solid lipid
nanoparticles distributed effectively throughout the lung alveoli in rats [59]. In vivo
12
(a) (b) (c)
(d) (e) (f)
Figure 5. Schematic illustration of commonly investigated types of nanoparticles. a)
liposome; b) micelle; c) polymer; d) dendrimer; e) inorganic; f) protein.
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dosing up to 200 μg of solid lipid nanoparticles by inhalation for 16 days showed little
inflammation in mice [60]. Entrapping celecoxib in solid lipid nanoparticles, when
dosed with i.v. docetaxel, decreases tumor size in mice [61]. These three studies
show the ability to dose and distribute therapeutics using lipid nanoparticles while
maintaining biocompatibility.
Lipid layers comprise micelles, improving absorption into cells. Micelles can ac-
commodate hydrophobic drugs up to 25% of the micellular weight [36]. Diacylphos-
phatidylethanolamine, a naturally occurring part of surfactant, added to pulmonary
formulations improves pulmonary delivery. Beclomethasone diproprionate in PEG-
diacylphosphatidylethanolamine formulations gained 1300 fold increase in solubility
and a 10 fold increase in release in vitro when incorporated into micelles [62].
Liposomes contain a lipid bilayer, like a cell membrane. Liposomes loaded with
ciprofloxacin offer the ability concentrate the dose in the lungs with little getting into
the system [63]. Liposomes made from lipids derived from an area to be targeted
improve biocompatibility. Lipid nanoparticles have a good safety profile, but can
undergo undesired reduction or hydrolysis reactions [64]. Lipids can be difficult to
customize, expensive to produce and challenging to ensure batch-to-batch consistency,
especially compared to polymers.
1.2.5.2 Polymers
Polymers as nanoparticle carriers offer the cheapest, most versatile characteris-
tics. Using polymeric colloidal drug carriers in pulmonary formulations is limited by
the unknown toxicity of the carrier in the lungs, and even biodegradable polymers
have not yet undergone any rigorous toxicity testing for ensuring safe delivery via the
lungs [35, 65].
Common polymers used to formulate nanoparticles include polyethylene glycol
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(PEG), poly(lactic-co-glycolic acid) (PLGA), poly-(ε)-caprolactone (PCL), chitosan,
alginate, or nucleotides. These polymers are combined to optimize size, surface and
release properties.
Microjet sprayed PLGA nanoparticles loaded with ciprofloxacin reduce mucus
turbidity and effectively treat bacterial infections [66]. Other PLGA nanoparticles,
loaded with Docetaxel [67], are undergoing phase II clinical trials.
Coating synthetic polymer particles has improved inflammation caused by poly-
mers in the lungs. Chitosan coatings increase the residence time of nanoparticles
in the lungs [68]. Chitosan can cause epithelial tight junction opening, resulting in
pulmonary edema [69].
Another possibility is oligonucleotides, which are nucleotide polymers meant to
bind to and specific RNA in diseases. Some oligonucleotides are poorly conserved,
making animal testing for nucleotides challenging to translate to human diseases.
They may accumulate systemically, causing associated non-specific immune responses,
and off-target cytotoxicity [70].
1.2.5.3 Dendrimers
Dendrimers are symmetric, repetitively branched molecules. They are monodis-
perse due to their high symmetricity and precise control of surface functionality.
Polyamidoamine (PAMAM), or polylysine are common polymers used in dendrimers,
with PEG to reduce toxicity. Because dendritic particles are precisely controlled,
inhaled dendrimers of different molecular weights can be distributed systemically or
localized to the lungs [71]. Dendrimers with surface cationic charge can serve as
promising vehicle for pulmonary delivery of bioactives, yet this same review article
cites significantly elevated toxicity with cationic dendrimers [72]. Current research
focuses on improving biocompatibility of dendrimers.
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1.2.5.4 Metals
Metal-based nanoparticles are commonly used for imaging, diagnostics, or toxic-
ity investigations. However, due to the cationic surface of metals, such as gold, some
inorganic nanoparticles are being looked at for gene delivery [73]. Nanoparticles which
use magnetization for targeting have received mixed results for both diagnostic and
therapeutic research. Proponents for this delivery method have shown magnets can
improve localization of particles to a specific region [74]. Opponents to this method
believe harm will occur before effective magnetization [75]. However, slow excretion
and inability to carry sufficient amounts of therapeutics hinders their clinical appli-
cations and long-term studies [73].
1.2.5.5 Proteins
An increasing number of new effective therapeutics are protein and peptide-
based, but they do not easily cross mucosal surfaces and biological membranes [76]
However, In vivo and In vitro stability issues arise due to the reactivity of some
amino acids. Therefore production with proteins must have tightly controlled pro-
duction conditions such as pH, temperature, agitation, ionic strength, and metal ions
or surfactants [77]. Protein clearance from the air spaces occurs around 1% hr-1, and
macrophages play a minimal role in protein clearance before 48 hours [78]. This same
study showed non-significant results between intubated groups versus non-intubated
groups suggesting the mucociliary escalator plays a minimal role in protein clear-
ance. Several authors prove an inverse relationship between the molecular weight of
macromolecules and their absorption rates [79, 80, 81].
Recent research has shown inhaled lung ECM (<10 μm particles) to be protective
against hyperoxia induced lung injury [82]. Another study found 250 μm urinary blad-
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der matrix-ECM particulate to be protective against bleomycin induced pulmonary
fibrosis [83]. As mentioned previously, the lungs are extremely efficient at removing
foreign particles from inhaled air. Therefore, by controlling the size of particles we
can control the deposition region, enabling particles to arrive at the region that is
most affected by basement membrane lysis, the bronchiole-alveolar junction.
By introducing extracellular matrix scaffolding into the lungs via inhalation we
may be able to shift the cellular microenvironment toward repair. Extracellular ma-
trix proteins provide a pro-regenerative, antimicrobial [84], and chemotactic proper-
ties [85]. Macrophages remodel the matrix to form de novo, site appropriate tissue
[86], or degrade the proteins through known biological processes. Many different ECM
matrices cause alternative (M2) macrophage activation [87], but lung-specific ECM
needs to be investigated.
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CHAPTER 2
RESEARCH DESIGN
2.1 Rationale and Major Hypothesis
This research began with the goal to deliver drugs using extracellular matrix.
Over the course of this research the goal has changed, now the objective is to form
particles which limit cytotoxicity, but meet the requirements to arrive at the distal
regions of the lungs. The change is due to the ambitious nature of the original research
question. We used the extracellular matrix from the lungs to increase biocompatibility
and induce other cell-level changes that could be beneficial in some lung diseases.
We hypothesize that a nanoparticle made from local extracellular matrix proteins,
would be compatible with alveolar epithelial cells and could induce a pro-regenerative
phenotype of macrophages. To test our hypothesis, we decellularized porcine lung
and electrosprayed it into small particles. We then characterized the particles, and
performed in vitro testing. In vitro, we quantified cytotoxicity of the particle when
added to alveolar epithelial-like cells, and examined the ability of the particles to
activate macrophages.
2.2 Specific Aims
1 Evaluate the ability to form nanoparticles from porcine lung extracellular ma-
trix, including particle sizing, ζ-potential, and passive degradation.
2 Determine the cytotoxicity of the porcine lung extracellular matrix nanoparti-
cles and the ability to shift macrophages to a pro-regenerative phenotype.
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2.3 Overview
Figure 6. Overview of nanoparticle production. Lungs are decellularized and milled into
powder. We then digest the powder in acetic acid for 48 hours before electrospraying the
resulting solution to form nanoparticles.
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* Sections taken from, Link et al., Tunable Hydrogels from Pulmonary Extracel-
lular Matrix for 3D Cell Culture, JOVE, 2017 will be marked with [88] *
3.1 Rationale
We needed a large amount of preprocessed tissue to conduct the experiments
mentioned. While it would be ideal to use species-specific extracellular matrix for
in vivo experiments, it would require numerous mice or rats which has not been
necessary so far. Human lung tissue is difficult to come by, making it unfeasible to
use tissue from humans. Therefore, we elected to use porcine lung as our source of
ECM, due to the accessibility of the tissue and the quantity of protein remaining after
processing. This chapter describes the methods for decellularization of porcine lung
tissue and forming the Porcine Lung Extracellular Matrix (PLECM) nanoparticles.
3.2 Methods
3.2.1 Decellularizing Lung Tissue
From [88]
1. Obtain, an en bloc normal porcine lung, from a slaughterhouse, with heart and
vasculature intact.
2. Use tissue scissors or a scalpel to dissect away the heart, cutting vasculature as
close as possible to the heart, remaining vasculature will be used in later steps
for perfusion.
3. Carefully dissect away the connective tissue surrounding the trachea, bronchi,
and vasculature using a scalpel or scissors.
NOTE: Determine the best lung to use for the rest of the procedure by choosing
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a lung without large cuts or punctures through the pleura and large amounts
of atelectasis or vascular occlusion that may impede the effectiveness of the
decellularization process.
4. Cut away the suboptimal lung leaving as much bronchus attached to the trachea
as possible (heart, connective tissue and the lobes of the removed lung may be
disposed of). There should be one lung remaining attached to the trachea and
vasculature.
NOTE: Retain sections for histology if desired.
5. Close disconnected bronchi with clamps or suture to prevent excess backflow.
6. Prepare the decellularization solutions and refrigerate at 4 °C until needed (Ta-
ble 1).
7. Using a hand pump cannulated to fit the pulmonary artery, perfuse the lung
tissue 3 times with DI water through both pulmonary artery and trachea. Per-
fuse vasculature first each time. Begin with around 1 L into vasculature and 1.5
L into trachea for each perfusion, but as cellular debris is removed more liquid
can be perfused through the system.
8. Perfuse both vasculature and trachea with Triton X-100 solution.
9. Submerge lung tissue in Triton X-100 solution for 24 hr at 4 °C.
10. Perfuse vasculature and trachea 3 times with DI water to rinse.
11. Perfuse both vasculature and trachea with deoxycholate solution.
12. Submerge the tissue sections in deoxycholate for 24 hr at 4°C.
13. Perfuse vasculature and trachea 3 times with DI water to rinse.
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14. Perfuse both vasculature and trachea with NaCl solution.
15. Submerge tissue in filtered NaCl solution for 1 hr at 4 °C.
16. Perfuse vasculature and trachea 3 times with DI water to rinse.
17. Perfuse both vasculature and trachea with DNase solution.
18. Submerge tissue in filtered DNase solution for 1 hr at 4 °C.
19. Perfuse both vasculature and trachea 5 times with PBS.
20. Dissect away noticeable cartilaginous tissue, trachea and all tubules 2 mm or
larger in diameter (primarily found around the hilum and medial portions of
the lungs) from conducting airways, leaving only respiratory zones (primarily
the peripheral areas).
21. Dissect tissue into 1 inch sections or smaller. Orientation of the tissue does not
matter for this step.
22. Pour off excess liquid and place tissue in 50 ml conical tubes. Freeze the tissue
at -80 °C.
NOTE: Retain sections for histology to ensure removal of cells and cellular
debris, if desired. We use H&E, α-galactosidase, picogreen, 9 hydroxyproline,
ninhydrin, alcian blue, SDS-PAGE, and mass spectrometry to characterize.
3.2.2 Decellularized Lung Processing
1. Remove lids from frozen tubes containing decellularized lung tissue.
2. Place filter paper over the tube opening and secure with rubber band.
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NOTE: Tube and contents should still be frozen otherwise place in -80 °C until
frozen.
3. Lyophilize the tissue until all excess liquid is gone, using a freeze dryer according
to manufacturer directions. Store at -80 °C until ready to mill.
4. Before beginning add liquid nitrogen to freezer mill to cool insulation and in-
ternal components to working conditions.
5. Remove magnetic mill bar from mill tube and add tissue to cover bottom.
6. Replace mill bar and add loosely packed tissue. The mill bar should still move
freely.
7. Close the mill tube and place in freezer mill.
8. Fill liquid nitrogen to max fill line.
9. Freezer mill all tissue into fine powder (approximately 5 min, impaction rate
of 600 min−1 ), in a polycarbonate cylinder with a stainless steel impactor as
well as stainless steel end plugs using the freezer mill according to manufacturer
directions. Store at -80 °C until ready for use.
From [88].
3.2.3 Particle Formation through Electrospray Deposition
We digested PLECM powder (5 mg/ml) in acetic acid:ultrapure H2O (80:20) un-
der constant agitation for 48 hours at room temperature. We then drew the resulting
solution into a plastic syringe (BD) fitted with a 27 gauge needle (BD, inner diameter
0.21 μm). We attached the syringe to a syringe pump (Kent Scientific, GenieTouch™)
set to 0.6 ml/hour. We placed the syringe pump and syringe were then placed on
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Table 1. Solutions Required for Tissue Decellularization. Make the solutions above for
the decellularization process. Store at 4 °C. Approximately 2.5 L will be needed for one
porcine lung.
Solution Sterile Filter Directions
DiH2O Yes DiH2O; Sterile Filter .
0.1% Triton X-100 Solution Yes Under fume hood add 100 μl Triton-X 100 Solution to 100
ml DiH2O and agitate until dissolved; sterile filter.
2% Deoxycholate Solution Yes Under fume hood add 2 g Sodium Deoxycholate solution
per 100 ml DiH2O and agitate until dissolved; sterile filter.
1 M NaCl Yes Add 58.44 g NaCl to 1 L of DiH2O; agitate until dissolved;
sterile filter.
DNase solution Yes Add 12,000 units DNase to 1 L DiH2O; Add 0.156 g MgSO4
(Anhydrous), and 0.222 g CaCl2 ; agitate until dissolved;
sterile filter.
PBS Yes Combine 27.2 g Na2HPO4· 7H2O (dibasic heptahydrate),
80 g NaCl, and 2 g KCl with 10 L DiH2O; agitate until
dissolved; adjust pH to 7.4; sterile filter.
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the top of a 1/2” Delrin® (polyoxymethylene) box with a hole drilled into it for the
syringe to pass through. Inside the box, an alligator clip connected the needle to
the voltage generator. Also inside the box, we grounded aluminum foil and placed
it 10 cm away from the needle tip. A voltage generator (Spellman CZE1000R) set
to 25 kV produced a voltage difference between needle tip and aluminum foil. Af-
ter nanoparticle formation, we sterilized the particles with 70% ethanol to remove
them from the aluminum foil. We diluted the ethanol solution with sterile ultrapure
water, so it would freeze. We lyophilized the nanoparticles, resulting in dry protein
based nanoparticles. We used dried nanoparticles immediately or stored them in a
desiccator until ready for use. Figure 6 shows an overview of the process.
3.3 Results
3.3.1 Decellularizing Lung Tissue
Decellularizing porcine lung tissue resulted in milled ECM protein, previously
characterized in [89]. Previous works have described histological results, composition,
and dsDNA content. Hematoxolin and eosin staining of the tissue indicated the
removal of most nuclei [89]. Picogreen assay of dsDNA indicated 95% reduction in
dsDNA over intact tissues [89]. Quantification of the major constituents revealed
reductions in collagen, elastin and glycosaminoglycans [89].
3.3.2 Particle Formation through Electrospray Deposition
To form the nanoparticles, we adopted a protocol developed for the electrospray
formation of collagen nanoparticles [90]. Collagen is the primary component of ex-
tracellular matrix, but ECM is a heterogenous mixture of numerous proteins so we
investigated methods to solubilize the components. Evaporating solvent induced nu-
26
merous chemical reactions between proteins which allowed the protein nanoparticles
to form (Table 2). We took micrographs of the formed particles after electrospray
deposition (Figure 7).
The electrospray formed a pulsating cone-jet (Figure 8, 16). A video of the pul-
sating cone-jet is in Appendix A. The pulsating cone-jet of the electrospray dispersion
formed polydisperse particles. Changes to the flow rate and voltage appeared to alter
the pulsation, with lower voltages and flow rates creating a more stable jet in general.
3.4 Discussion
We successfully formed nanoparticles by electrospraying the decellularized extra-
cellular cellular matrix proteins. As expected, decellularizing lung tissue with harsh
detergents resulted in the lysis of cellular membranes, and the removal of the majority
of cellular components. As with all biomaterials, immunogenicity is a large concern.
In porcine species, the α-galactosidase (α-GAL) enzyme, which causes rejection of
xenogenic tissue transplants. Decellularization of porcine lungs has resulted in signif-
icant reductions of α-GAL [89]. However, by modifying the porcine genome to express
human α-GAL may be a method to minimize xenogenic rejections [91]. Therefore, if
it is possible to use porcine lung by mitigating immunogenic reactions, it would be
possible to scale up the tissue to a much larger scale.
We chose to digest the proteins in acetic acid because acetic acid digests proteins
slower than other acids [92], disrupts bacterial biofilms [93] and is an electrospray
solvent [90]. However, aerosolized acetic acid is an irritant to the respiratory system
and eyes, so we elected to electrospray inside of a chemical hood. We added the
Delrin box to insulate the electrospray setup from the air flow and other chemical
waste vapors from affecting the nanoparticle production. Trial and error led us to
using a 27 gauge needle, we wanted to minimize the internal diameter for smaller
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Figure 7. Representative image of PLECM electrosprayed to form nanoparticles. The
particles were lyophilized, coated with platinum and then imaged using a scanning electron
microscope. The particles shown have a size range of 70-420 nm. Scale bar 100 nm
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Figure 8. A pulsating cone-jet formed at the tip of the needle. The electrospray param-
eters of 25 kV with a distance of 10 cm the parameters used to electrospray the PLECM
nanoparticles.
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particle sizes, but not all proteins digested in the acid solution which would cause
clogging of smaller needles.
Acid digestion of the powder from the decellularized tissue resulted in a solution
capable of being electrosprayed. Due to the diversity of protein digestion and pro-
teins in the solution we believe the pulsation was intrinsic, meaning it was a natural
pulsation. Most applications prefer steady cone-jets, however pulsating cone-jets are
frequently encountered [94]. Trying to scale-up the production through commercial
electrospray reduces efficiency to 30-40% [95]. Therefore, additional studies looking
to optimize this system could find an optimal balance between flow rate and cone
stability to increase the efficiency of particle formation.
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4.1 Rationale
After forming particulate, we needed to determine that characteristics of the
particles. We would like to make this a scalable procedure so we ran initial procedures
to determine the feasibility of the procedure. However, we learned after most of the
data was complete that we could improve the electrospray settings to improve our
efficiency. We mention these in the discussion and the future directions (Chapter 6).
This chapter describes the methods for characterization of the PLECM nanoparticles.
4.2 Methods
4.2.1 Nanoparticle size and charge
We characterized the formed nanoparticles through Scanning electron microscopy,
particle sizing (Malvern Zetasizer ZN90), ζ-potential determination (Zetasizer), and
western blots. To obtain scanning electron microscope (SEM) images, we sprayed
particles onto a silicon wafer (Ted Pella, 16015). We affixed the silicon wafer to an
aluminum specimen mount, (Ted Pella Inc, 16324). We then placed the sample in the
scanning electron microscope (SEM) an and focus was obtained at 2-3 fold increased
magnification desired for the image.
We measured particles sizes and ζ-potential using a zetasizer (Malvern, ZS-90).
To determine particle sizes, we resuspended 0.5 mg·ml−1 dried nanoparticles in 0.9%
saline and pipetted the suspension into a disposable cuvette (Malvern, DTS0012).
We then used dynamic light scattering to size particle solution. To determine ζ-
potential, we resuspended 0.5 mg·ml−1 dried nanoparticles in ultrapure water pipetted
the suspension into a Universal Dip Cell (Malvern, ZEN1002). We then placed the
cuvette or Dip Cell in the zetasizer and run for 200 cycles.
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4.2.2 Mucus penetration
We made artificial sputum (ASM) as per [96]. In brief, we added the follow-
ing to 100 mL ultrapure water: Bovine Serum Albumin (BSA) 10 mg·mL−1 (Fisher
Scientific); porcine stomach mucin 10 mg·mL−1 (Sigma); and herring sperm DNA
1.4 mg·mL−1 (Sigma). We then adjusted the mixture pH to pH 6.5. The mixture
was stirred and homogenized for 5 min solubilize the ingredients. For the mucus
penetration, we added 100 μL of the ASM to a 96-well plate on a microscope. We
identified and focused on particles of the BSA for the experiment duration. We pipet-
ted nanoparticles suspended in 0.9% saline on the top of the mucus slowly, to prevent
agitation. Images were taken every minute for one hour.
We used the Particle Tracker plug-in to process the images [97] in ImageJ [98].
We used images beginning at 5 minutes after nanoparticle addition, where the mu-
cus stopped oscillating, until 30 minutes, where most particles had passed through
the visible plane. We determined mucus penetration using the calculated velocities
based on a possible thickness of 100 μm and mucociliary escalator transport rate of
5 mm·min−1 [51] and a distance from alveoli to trachea of 150 mm [37].
4.3 Results
4.3.1 Nanoparticle size and charge
The formed nanoparticles had an average size of 225 (± 67) nm and a ζ-potential
of -10 (± 1.6) mV. The nanoparticles are considerably smaller than cryomilled PLECM
in ultrapure H2O - 7918 (± 5405) nm and -17 (± 23) mV - and acetic acid digested
particles - 3923 (± 4271) nm and 5.5 (± 4.9) mV.
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Table 2. Sizes and ζ-potentials of extracellular matrix proteins in different solutions.
Formed nanoparticles are smaller than intact ECM in ultrapure H2O, and digested ECM
in Acetic acid.
Solution Concentration Size ζ-potential
PLECM Nanoparticles in ultrapure H2O 0.5 mg/ml 225 (± 67) nm -10 (± 1.6) mV
PLECM in ultrapure H2O 0.5 mg/ml 7918 (± 5405) nm -17 (± 23) mV
PLECM in 80% Acetic Acid 0.5 mg/ml 3923 (± 4271) nm 5.5 (± 4.9) mV
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4.3.2 Mucus penetration
Nanoparticle aggregates moved through the ASM at all time points after added
to mucus (Figure 9). Large particulate was seen before addition of nanoparticles.
The BSA particulate was used to determine if the particles were added with too
much force, affecting the mucus penetration. Image analysis using particle tracking
software determined movement vectors for each particles in the field of focus. We
calculated velocities through the mucus using the distance vectors and time (Figure
10). We calculated the average speed of the nanoparticle through the ASM to be
5.445 ± 0.07784 μm·min−1.
4.4 Discussion
These particles may possess a significant advantage over other carriers because
our results indicate these protein nanoparticles could penetrate mucus. Our results
show that the nanoparticles are sized appropriately for alveolar deposition. Addition-
ally, these particles possess a mild negative charge, implying improved biocompati-
bility. ζ-potential
Nanoparticle size is an important characteristic in initial determinations of dis-
tribution, deposition, cellular uptake, and mucus penetration. To deposit in the lower
regions of the lungs nanoparticles must be smaller than 300 nm (See Section 1.2.1).
As particle size increases, nanoparticles deposit more proximal in the lungs (toward
the trachea). A polydisperse treatment could be expected to treat the whole lung. In
large airways (>2 cm), increased mucus production and smooth muscle enlargement
are prominent, but these changes are minor contributors to the symptoms endured
[25]. Therefore using a polydisperse treatment with a majority of particles around
100 nm could be expected to produce symptomatic relief from the lower airways, but
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Figure 10. Vectors created from nanoparticles added to artificial sputum .
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also slow the disease progression in the larger airways.
Optimizing surface charge requires a balance between agglomeration, cellular
uptake and cytotoxicity. Increased ζ-potential is commonly associated with cytotoxi-
city. Positively charged chitosan-PLGA nanoparticles increased cytotoxicity over neg-
atively charged PLGA nanoparticles [68], even though chitosan has commonly been
described to decrease cytotoxicity. The electrosprayed protein nanoparticles display
a slightly negative ζ-potential, indicating they should be less toxic, with decreased
cellular uptake. However, because of the relatively neutral charge we expect some
agglomeration of the nanoparticles, which may impact distribution. In addition to
distribution, the heterogeneous composition and only partial digestion might cause
differences in ζ-potential between particles which may impact toxicity and release
characteristics. Decreased cellular uptake would be beneficial for antibiotic delivery
or long-acting immunomodulators, but not for emergency-type therapeutics such as
albuterol. In COPD, patient compliance is a major problem for therapies, so ex-
tending the drug release duration may improve patient symptoms. By maintaining
a mild negative surface charge, we may see increased alveolar distribution due to
electrostatic repulsion from the cell membranes and mucus.
In the lungs, the particles will come in contact with respiratory fluid. Hyper-
secretion of mucus seen in COPD increases the likelihood that particles will come into
contact with mucus rather than surfactant. We wanted to ensure the nanoparticles
could penetrate mucus. The calculated average speed of nanoparticles, 5 μm·min−1
is much faster than mucus transport by the mucociliary escalator. Based on the
transport rates outlined in Section 1.2.3, it would take less than 2 minutes for the
nanoparticles to penetrate the mucosal layer in the trachea, which would be much
thinner in the airways. As demonstrated these nanoparticles maintain a mild nega-
tive ζ-potential, electrostatically repelling mucus which maintains a negative charge.
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Additionally mucus is though to have a pore size of 0.2 μm - 15 μm, depending
on hydration status and infection [99]. Other studies have shown that PEGylated
nanoparticles <500 nm can effectively penetrate mucus, while particles larger than
500 nm are immobilized [100]. These results were expected based on particle size,
charge, and hydrophobicity.
The results of the characterization work provided a solid basis for in vitro testing
to determine the biocompatibility of these particles.
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5.1 Rationale
To elucidate therapeutic potential of the formed nanoparticles, we investigated
the in vitro cytotoxicity. Cytotoxicity occurs if a biomaterial causes cells to die, and
a sub-lethal dose can cause cells to stop proliferating. It is a very important in the
research development phase to determine cytotoxic effects,. Cytotoxicity provides a
cheap and easy method to see if a potential therapeutic is worth pursuing.
We used Cell Counting Kit-8 (CCK8; Dojindo Molecular Technologies) , a col-
orimetric cell viability assay. It uses total cell dehydrogenase activity to reduce a
tetrazolium salt , producing a yellow formazan dye. Additionally, it is not toxic to
cells and does not require cell lysis so other cell proliferation assays can be performed
in conjunction.
After establishing a safe range and a dose comparable to the control, we investi-
gated the inflammatory response to the nanoparticles. Macrophages are a major part
of the innate immunity. They are a first responder to pathogens, insults, and injuries,
phagocytizing foreign objects or initiating an immune response through cytokine re-
lease. Besides starting an immune cascade, macrophages play a major role in tissue
regeneration and remodeling. As such, macrophages are a key cell in the patholog-
ical changes associated with COPD. Therefore by modifying macrophage behavior,
we can begin to address the abnormal immunological response seen in COPD, and
possible repair the damaged tissues.
5.2 Methods
5.2.1 Cytotoxicity
We grew lung epithelial cells, A549s, in RPMI 1640 media (Gibco) with 10%
fetal bovine serum (FBS) and 1% Penicillin/Streptomycin. To each well of a 96-
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well plate, 10,000 cells were added and allowed to attach overnight. We resuspended
nanoparticles in media to the desired concentrations and serially diluted for sub-
sequent concentrations. We replaced the media in each well with the nanocarrier
dilutions and left for 24 or 48 hours. After the desired time, we washed the cells with
PBS and then CCK8 (Dojindo) in media was added to each well, as per manufac-
turer’s instructions. After 4 hours in CCK8, we read the 450 nm absorbance using a
microplate spectrophotometer (BioTek Epoch).
5.2.2 Macrophage Response
We isolated bone-marrow derived macrophages (BMDM) from femurs and tibia
bones from C57BL6 mice. We then cultured them in RPMI with 20 ng/ml M-CSF
(BioLegend 576404), with 10% FBS, 1% P/S, 1% sodium pyruvate and 1 mM HEPES
(M∅ phenotype) for 1 week, as described by [101], with a media change on day 3. On
Day 7, we added 0.5 mg·mL−1 nanoparticles in BMDM culture media, based on
cytotoxicity results (see Section 5.3.1) for 24 hours. To control for phenotypic shift
we activated BMDMs with M1 or M2 activating media for 24 hours. M1 activation
media comprises RPMI with 10% FBS, 1%P/S, 1% sodium pyruvate, 1 mM HEPES,
100 ng·mL−1 lipopolysaccharide, and 50 ng·mL−1 interferon γ (BioLegend 575304).
M2 activation media comprises RPMI with 10% FBS, 1% P/S, 1% sodium pyruvate, 1
mM HEPES, 10 ng·mL−1 IL-4 (BioLegend 574302), and 10 ng·mL−1 IL-13 (BioLegend
575902).
After 24 hours with activation media or with nanoparticles, we performed Flow
cytometry to identify population shifts of activated macrophages. We aspirated me-
dia off the plates and then washed them one time with PBS. Next, we added Accu-
tase® (innovative cell technologies) to detach the cells for 30 minutes at 4°C. We
collected the cell suspension in 5 mL tubes, and then washed the plates with Flow
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Buffer (5% FBS in PBS) and added to the collection tubes. We centrifuged the cell
suspensions at 500 g (rcf) for 5 minutes at 4°C. We removed the supernatant and
resuspended the cells in 100 μL Flow Buffer. We then added an CD16/32 antibody
(1.25 μg) to block the Fc-receptors for 15 minutes at room temperature to prevent
non-specific binding and false-positives. We added 0.2 ng of the remaining antibodies
(BD Biosciences) – CD80 (BV421; 562611), CD206 (AF647; 565250), F4/80 (PE-
A; 565410), CD11b (BUV395; 565976), CD11c (BV786; 563735)– in 50 μL of Flow
Buffer and added to the cell suspension (single antibody controls and no antibodies
were used as controls). The cell-antibody suspension sat for 30 minutes in the dark
at room temperature. We centrifuged the cell suspensions at 500 g (rcf) for 5 minutes
at 4°C. After discarding the supernatant, we washed the cells twice with 1 mL Flow
Buffer and centrifuged as before. We then removed the supernatant and resuspended
the cells in 1% paraformaldehyde in Flow Buffer to fix the cells. The cell suspension
sat for 30 minutes in the dark at 4°C. We centrifuged the cell suspensions at 500 g
(rcf) for 5 minutes at 4°C. After discarding the supernatant, we washed the cells twice
with 1 mL Flow Buffer and centrifuged as before. We then resuspended the cells in
0.5-1 mL Flow Buffer and stored overnight at 4°C.
We established a flow panel (Figure 11) by adding single color controls to Ultra-
Comp eBeads (01-2222-41, Thermo Fisher Scientific). Then we used the single color
controls with cells, followed by the Fluorescence Minus One (FMO) controls with cells
and then cells without stained cell-surface markers. Last, cells with all markers were
sorted through the Flow Cytometer. We used Forward and Side Scatter to create
the first gate. We then used +F4/80/+CD11b to establish the second gate. Cells
meeting both previous criteria were then used to determine macrophage activation.
Cells stained +CD11c/-CD206 were identified as M1. Cells stained -CD11c/+CD206
were identified as M2.
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Figure 11. Flow panel schematic to determine macrophage activation. We used forward
and side scatter to establish gate one (Purple). We then created gate two by identifying
F4/80+/CD11b+ cells. Finally, we used CD11c+/CD206- to identify M1, and CD11c-
/CD206+ to identify M2.
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5.2.3 Statistical Analysis
We calculated statistical significance using Prism 7 (GraphPad). We conducted
One-way ANOVA and Tukey’s multiple comparisons test for groups with three or
more variables. We assumed statistical significance at p<0.05.
5.3 Results
5.3.1 Cytotoxicity
Lung epithelial cells treated with nanoparticles increased cellular proliferation of
A549 cells at both 24 and 48 hours. After 24 hours, cells with 0.25 mg/ml had a sig-
nificant increase in proliferation of 19.4%. We measured the proliferation through col-
orimetric dehydrogenase activity. After 48 hours, cells with 0.125 mg·mL−1 nanopar-
ticles added had significantly better proliferation than the control cells. Additionally,
after 48 hours, 1 mg·mL−1 nanoparticles significantly decreased cell proliferation. We
chose a concentration of 0.5 mg·mL−1 for follow-on experiments because it is not
statistically different from the control in terms of cellular proliferation.
5.3.2 Pro-regenerative activation of macrophages
After 7 days of culture with M-SCF, monocytes showed minimal amounts of
CD11c and a moderate amount of CD206 we defined them them Na¨ıve macrophages
(Figure 14). Na¨ıve macrophages then received inflammatory (M1), pro-regenerative
(M2), nanoparticles, or no treatment to identify phenotypic shift. In vitro, the
BMDMs identify the formed nanoparticles after we added the nanoparticle aggre-
gates to the cell media (Figure 15). When added to unactivated na¨ıve macrophages
for 24 hours, nanoparticles caused significant increases in M2 cell-surface markers
Figure 14a, with significant decreases in M1 cells surface markers (Figure 14b). M2
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(a) (b)
Figure 12. ECM protein nanoparticles increase cellular proliferation. a) Nanoparticles
added to A549 cells for 24 hours b) Nanoparticles added to A549 cells for 48 hours. Data
shown are mean ±SD. * indicates p <0.05; ** indicates p <0.01; *** indicates p <0.001
n=3
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(a)
(b)
(c)
Figure 13. At low concentrations, nanoparticles added to cells do not change proliferation.
Representative image of Live/Dead staining after nanoparticle addition for 24 hours. a)
Control cells; b) 0.125 mg·mL−1; c) 0.25 mg·mL−1.
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activated cells did not have significantly different CD11c-/CD206+ compared to M0.
M1 activated macrophages showed significant increase in M1 markers compared to
M0. Unactivated macrophages, in the absence of activators, showed a baseline ex-
pression of surface markers similar to M2 activated macrophages when stained for
M1 markers, and M1 activated macrophages when stained for M2 surface markers.
5.4 Discussion
We show here that the formed protein nanoparticles increase epithelial cell pro-
liferation, and decrease the inflammatory surface markers, while increasing the pro-
regenerative surface markers of BMDM. As expected, using a base of naturally de-
rived proteins increased cellular proliferation. At much lower concentrations, hy-
perbranched polyamidoamine (PAMAM) of equivalent size decreases proliferation by
10% in HEK293 and COS7 cells compared to control cells without nanoparticles
[102]. Equivalently sized chitosan particles at similar concentrations found no change
to proliferation at similar doses [103]. The increase in cellular proliferation could
have a dramatic effect in COPD patients that commonly experience cellular apopto-
sis as part of the disease (Section 1.1.1). Besides increasing cellular proliferation, the
formed nanoparticles increase pro-regenerative surface markers of BMDMs.
Macrophages identify most particulate which enters the alveoli. Because macrophages
identify the particulate in the alveoli, they exist on a spectrum which governs their
response and the factors they release. Inflammatory macrophage activation is a key
contributor to COPD. While many nanoparticles induce M1 phenotype, few cause
M2 phenotype shift, and fewer have shown the ability to reprogram M1 to form M2
macrophages [104]. Of the few that have been shown capable of reprogramming
macrophages, natural materials, such as such as hyaluronic acid [105] or alginate
[106], loaded with plasmids for gene transfection. Others have shown specific peptide
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(a) (b)
Figure 14. Nanoparticles induce a pro-regenerative macrophage phenotype. Nanoparticles
added to na¨ıve macrophages cause increases in the M2-related surface marker CD206, and
decreases in the M1-surface marker CD11c. a) Percentage of parent cells expressing M1 cell
surface marker CD11c+/CD206-; b) Percentage of parent cells expressing M2 cell surface
marker CD11c-/CD206+. Data shown are mean ±SD. * indicates p <0.05; ** indicates p
<0.01; *** indicates p <0.001; **** indicates p <0.0001 n=2
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(a)
(b)
Figure 15. In vitro nanoparticles are identified by macrophages. Macrophages migrate
to identify nanoparticle aggregates. a) Nanoparticles (Red) added to na¨ıve macrophages.
b) Nanoparticles added to M1-activated macrophages. 100 μm scale
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sequences added to nanoparticles cause polarization to M2 using RGD, or M1 through
GLF peptides [104]. Pro-regenerative, M2, macrophage activation occurs in response
to ECM from other sources [87]. In COPD, pro-regenerative macrophages could be
therapeutic, repairing some of the damage that occurs with the disease.
These PLECM nanoparticles induce a pro-regenerative phenotype in macrophages,
presumably through phagocytosis. Phagocytosis has been show to increase with in-
creasing magnitudes of ζ-potential, opsonins, and fibronectin [107]. Targeting the
phagocytic process of macrophages with therapeutics can be beneficial in COPD
using both immunomodulators, and antibiotics, as bacterial infections such as S.
pneumoniae can impair macrophage function [108]. However, since the macrophage
response is already impaired in COPD, the particles must release active drug in the
extracellular space. We decided to use proteins because, in addition to being phago-
cytosed by macrophages, the excess proteases in COPD will break down the particles.
Protease degradation will release the desired therapeutic in the extracellular space.
We believe the Mannose Receptor of the macrophages recognizes these nanopar-
ticles. The Macrophage Mannose Receptor recognizes collagen, independent of car-
bohydrates [109]. Macrophage endocytosis can occur through the MR, in addition to
other pathways [110]. We used CD206 as a marker for M2 activation, but since CD206
is the mannose receptor, so future investigations should look at another M2 marker for
flow. Alternatively, we could perform qPCR to identify upregulated pro-regenerative
markers.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
We have formed a protein nanoparticle from the extracellular matrix of porcine lung.
Decellularization of the lung provided a good starting material for the nanoparticles.
Decellularized lung has previously been characterized in [89, 111]. Acetic acid digest
of the decellularized powder solubilized most of the powder. Changes to the acid
or the addition of proteases, such as HCl and pepsin, could increase the solubility
[89]. Changing the solution impacts the conductivity of the solution, impacting the
ability to electrospray the particles; only certain solutions can be electrosprayed [112]
Characterization of the protein that was not soluble may provide an initial method
to optimize particle formation, and increase efficiency.
Future studies could optimize electrospray settings, voltage, distance, solution
conductivity, to decrease particle dispersion. These settings all contribute to Taylor-
Cone formation is a significant contributor to particle size consistency. Increasing
efficiency would improve drug encapsulation, which would ensure the correct dosage
was being given to patients. However, the proteins found in the ECM have inherent
charges associated with their structures, so by having a variable composition there
will be variability between particles. By adding different salts to the solution, we
can tailor the solution conductivity, and ζ-potential [90]. The current settings form
polydisperse particles aimed to distribute throughout the lungs, to treat all regions
affected in COPD.
Before nanoparticles can treat COPD, they must pass through the excess sputum
found in the disease. We found that the formed particles penetrate mucus much
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faster than the mucociliary escalator expels mucus from the respiratory tract. Adding
an antibiotic to the surface of the nanoparticles, may deliver the antibiotic to the
mucus, targeting the bacterial colonies formed in the mucus. Other groups have
shown inherent antibacterial activity [84], which may exist in these nanoparticles.
Making it through the mucus, the nanoparticles will encounter the epithelial cells,
some of which are are undergoing apoptosis [18, 19, 16]. These nanoparticles increase
proliferation, potentially halting the goblet cell hyperplasia, and therefore mucus
hypersecretion.
After making it into the alveoli, the particles will face inflammatory activated
macrophages. Inflammatory macrophages contribute significantly to the COPD pathol-
ogy [28]. These engineered nanoparticles have the ability to shift macrophages to a
pro-regenerative phenotype. In vivo testing of the nanoparticles would determine
if these results might translate to human clinics. One of the major concerns with
xenogenic biomaterials is immunogenicity; adding them to the macrophages did not
shift the macrophages to an inflammatory phenotype. The decellularization process
has proved to remove most immunogenic materials [89], the additional acid digestion
could improve these results. We have engineered the PLECM derived nanoparticles to
reduce immune reactivity and shift the macrophages to a pro-regenerative phenotype.
This investigation demonstrates the potential for these nanoparticles to treat
disease. However, a large amount of work must be done before these nanoparticles
can be used in humans. Besides in vivo characterization, adding therapeutics to the
nanoparticles is needed to elucidate optimal treatments for the carriers. Also, a better
understanding of the composition would be help determine which proteins could be
used individually, or in combination, to improve particle consistency. Additionally,
investigations into the mechanism of action for pro-regenerative macrophage activa-
tion would benefit this project as well as the field of tissue engineering. The particle
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described herein possesses a lot of potential to become a carrier for therapeutics and
a nano-sized scaffold for lung regenerative medicine.
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Appendix A
VIDEO OF PULSATING CONE-JET
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Figure 16. Video of pulsating cone-jet.
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